Key takeaways:
Wegovy (semaglutide) and Saxenda (liraglutide) are both injectable medications that are FDA approved for weight loss. Wegovy is injected once weekly. Saxenda is injected once daily.
During a study comparing Wegovy and Saxenda for weight loss, people using Wegovy lost significantly more weight than people using Saxenda. And a smaller percentage of people stopped using Wegovy compared to Saxenda.
Wegovy is also approved for certain cardiovascular benefits in people with heart disease and larger body size. Saxenda is not approved for this purpose.
There are ways to save on Wegovy and Saxenda, which are available as brand-name medications. Savings opportunities such as manufacturer copay cards can help make your prescription more affordable.
In 2014, Saxenda (liraglutide) became the first medication of its kind to be approved for weight loss. Its use was then expanded to include adolescents ages 12 to 17 in 2020. A year later, the FDA approved a similar medication called Wegovy (semaglutide).
There are several other medications available for weight loss. Yet, more medications like Saxenda and Wegovy are being studied due to their potential for better results. But is one better than the other? Below are five differences between Wegovy and Saxenda to consider.
Wegovy lasts longer in the body compared to Saxenda. Because of this, you don’t have to inject it as often. Wegovy is injected once a week, while Saxenda is injected once daily.
You should inject your Wegovy dose on the same day each week, at any time of day. Similarly, you can inject your Saxenda dose at any time of day. But it may be helpful to create a routine by picking a specific time and sticking with it, especially with daily injections.
With both Wegovy and Saxenda, you don’t need to time your dose around meals. You also have three injection sites to choose from — just under the skin on the upper arm, thigh, or abdomen. It’s best to rotate where you inject each time to prevent lumps from forming under the skin.
Medication | Recommended dosage | Injection schedule |
---|---|---|
Saxenda | Starting dose: 0.6 mg Target dose: 3 mg | Daily |
Wegovy | Starting dose: 0.25 mg Target dose: 1.7 mg or 2.4 mg | Weekly |
Wegovy and Saxenda are both glucagon-like peptide-1 (GLP-1) receptor agonists. Although they work the same way in the body, their results may be different. Current evidence suggests that Wegovy works better for weight loss than Saxenda when combined with a lower-calorie diet and regular exercise.
A 68-week study compared Wegovy and Saxenda in over 300 adults. The results showed that people using Wegovy lost significantly more weight compared to those using Saxenda. The Wegovy group lost an average of roughly 16% of their initial body weight. This is compared to about 6% in the Saxenda group.
GLP-1 savings guide: Learn about ways to save on glucagon-like peptide-1 (GLP-1) medications, such as Ozempic (semaglutide), with GoodRx discounts, copay savings cards, and more.
Stopping Wegovy: Wegovy (semaglutide) is meant to be used long term for weight loss. But here’s what happens if you stop taking it.
GLP-1 side effects: Feeling nauseated after injecting Wegovy or Saxenda (liraglutide)? Here’s a list of GLP-1 side effects and how to manage them.
Before the results of this study were published, other studies reported similar findings. The largest Wegovy trial had nearly 2,000 participants and reported an average weight loss of nearly 15%. A Saxenda trial with over 3,700 participants reported about 8% average weight loss.
The head-to-head study mentioned above also compared side effects and discontinuation rates between Wegovy and Saxenda. Based on the findings, it’s possible that some people might tolerate Wegovy better than Saxenda.
During the study, gastrointestinal (GI) side effects were more common with Wegovy. But a larger percentage of people ended up stopping Saxenda, half of which were due to side effects. There were also higher rates of gallbladder problems and insomnia reported with Saxenda.
These differences aside, Wegovy and Saxenda have many overlapping side effects. GI side effects, such as nausea, diarrhea, and stomach upset, are common. They’re usually worse when starting treatment and after dose increases. But for many people, they usually improve over time.
In the table below, we compare the percentage of people that reported experiencing particular side effects when taking Saxenda and Wegovy during the study.
Side effect | Saxenda | Wegovy |
---|---|---|
Nausea | 59% | 61% |
Constipation | 32% | 39% |
Diarrhea | 18% | 28% |
Vomiting | 21% | 25% |
Headache | 14% | 16% |
Burping | 4% | 14% |
Decreased appetite | 13% | 12% |
Fatigue | 11% | 10% |
11% | 0% |
Keep in mind that everyone responds to medications differently. For example, you may have more difficulty tolerating Wegovy compared to Saxenda (or vice versa).
Wegovy and Saxenda injection pens work differently, which is good to keep in mind if you switch from one product to the other. Wegovy pens are used one time, while Saxenda pens are meant for multiple uses.
Wegovy comes in a single-use prefilled pen that’s available in five different doses. The pen is ready to use with the needle already attached. Since each Wegovy pen is used one time, you’ll throw it away after injecting your dose. Wegovy pens last the longest when they’re stored in the refrigerator prior to use.
Saxenda comes in a pre-filled multi-dose pen, which means each pen is used more than once. The Saxenda pen contains five different dose options — you need to select your specific dose prior to injecting. It doesn’t come with needles, so those must be purchased separately. Saxenda pens should also be stored properly before and in-between uses.
Unlike Saxenda, Wegovy is approved for certain cardiovascular benefits in people with heart disease who are considered overweight or obese. Specifically, it can lower the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death), or MACE.
During a 5-year clinical trial, Wegovy was shown to lower the risk of MACE by 20% compared to placebo (an injection without medication in it). These benefits began early in treatment, even before participants lost a significant amount of weight.
If you have heart disease, your prescriber may recommend Wegovy over Saxenda due to these additional cardiovascular benefits.
Yes. It’s possible to switch from Saxenda to Wegovy. Since Wegovy can result in greater weight loss, you may decide to make the switch if Saxenda isn’t working well enough for you. Your prescriber may have you start with a lower Wegovy dose and work your way up to lessen side effects.
Wegovy remains in high demand and may not be covered by insurance. So if you’re having difficulty filling your prescription, your prescriber may switch you from Wegovy to Saxenda if it’s more accessible. However, there isn’t a Saxenda dose that’s comparable to the Wegovy dose recommended for weight loss.
Talk to your prescriber if you’re considering switching from one medication to another. They can help you understand your options and best next steps.
There are ways to save on Wegovy and Saxenda, which are available as brand-name medications. Manufacturer copay cards, GoodRx coupons, and direct pharmacy options can help make your prescription more affordable.
Manufacturer copay cards: If you have commercial insurance that covers Wegovy, you could pay as little as $0 per month with a copay savings card. If your commercial plan doesn’t cover Wegovy or you’re uninsured, the price is as low as $499 per month.
GoodRx coupons: Save 14% off the average retail price of Wegovy and 15% off the average retail price of Saxenda with a free GoodRx coupon.
Direct pharmacy options: Get Wegovy delivered to your door for as low as $499 through NovoCare Pharmacy.
GLP-1 medications like Saxenda and Wegovy aren’t right for everyone. Your healthcare team will review your health history to determine if they’re safe to use. But you typically shouldn’t use a GLP-1 if you:
Have a personal or family history of medullary thyroid cancer
Have an inherited condition called multiple endocrine neoplasia syndrome type 2
Are pregnant or planning to become pregnant
Have had a serious allergic reaction to Saxenda, Wegovy, or any of their ingredients
Have a history of pancreatitis or severe gastrointestinal problems (such as gastroparesis)
Weight loss from Saxenda or Wegovy can take time, and not everyone responds to these medications the same way. But there are a few possible reasons why you may not be losing weight:
Your dose hasn’t been increased to the target dose yet
Lifestyle changes, such as your diet, exercise, and sleep habits, may need adjustments
Your body may be slower to respond or adapting to the medication
Certain medications or health conditions may interfere with weight loss
Wegovy, Saxenda, and Ozempic (semaglutide) are all GLP-1 receptor agonists. But there are a few key differences:
Ozempic is a weekly injection approved for Type 2 diabetes in adults, not weight loss. But it’s often prescribed off-label for that purpose.
Wegovy contains the same active ingredient as Ozempic. But it’s approved for weight loss at higher doses for certain people ages 12 and older.
Saxenda is approved for weight loss for certain people ages 12 and older. It contains liraglutide instead of semaglutide and is injected daily.
Wegovy (semaglutide) and Saxenda (liraglutide) are both injectable glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. But Wegovy is injected weekly, while Saxenda is injected daily. Greater weight loss and heart protection are also possible with Wegovy.
If other weight-loss medications haven’t been working for you, check with your prescriber. They may recommend Wegovy or Saxenda as a good option for you.
Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine.
National Cancer Institute. (n.d.). Multiple endocrine neoplasia type 2 syndrome. National Institutes of Health.
NovoCare. (2025). NovoCare Pharmacy.
Novo Nordisk. (2020). FDA approves Saxenda for the treatment of obesity in adolescents aged 12-17.
Novo Nordisk. (2025). Saxenda liraglutide injection 3mg [package insert].
Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. The New England Journal of Medicine.
PR Newswire. (2014). Novo Nordisk receives FDA approval for Saxenda (liraglutide [rDNA origin] injection) for chronic weight management.
PR Newswire. (2025). In new SELECT trial analysis, early reduction in cardiovascular events was observed with Wegovy, before clinically meaningful changes in body weight.
Rubino, D. M., et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA.
U.S. Food and Drug Administration. (2024). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight.
Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine.